Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

EMA Grants a Positive Opinion for LysaKare (Arginine/lysine)

It is intended for protecting the kidneys against radiation during PRRT with lutetium (177Lu) oxodotreotide
03 Jun 2019
Palliative and supportive care

On 29 May 2019, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product LysaKare (Arginine/lysine),intended for protecting the kidneys against radiation during radioactive therapy with lutetium (177Lu) oxodotreotide.

The applicant for this medicinal product is Advanced Accelerator Applications.

LysaKare will be available as 25 g / 25 g solution for infusion.

The active substances of LysaKare are the amino acids L-Arginine Hydrochloride and L-Lysine Hydrochloride (ATC code: V03AF11) that decrease reabsorption and retention of lutetium (177Lu) oxodotreotide in the kidney tubules.

The benefits with LysaKare are its ability to reduce exposure of the kidneys to radiation from lutetium (177Lu) oxodotreotide.

The most common side effects are nausea and vomiting.

The full indication is: “Reduction of renal radiation exposure during peptide-receptor radionuclide therapy (PRRT) with lutetium (177Lu) oxodotreotide in adults.”

It is proposed that LysaKare be administered by physicians experienced in radioactive therapy.

Detailed recommendations for the use of this product will be described in the summary of product characteristics, which will be published in the European public assessment report and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion.

Last update: 03 Jun 2019

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.